medwireNews: Superior lowering of amyloid plaque with donanemab compared with aducanumab in patients with early symptomatic Alzheimer’s disease (AD) extends to 18 months, show findings from the TRAILBLAZER-ALZ 4 trial.
12-03-2024 | Alzheimer's Disease | News
AD/PD 2024